Table 1.
Characteristics of the study group.
| Parameter | Median (IQR)1
n = 319 |
|---|---|
| Gender (female/male) | 230 (72%) / 89 (28%) |
| Age at initial presentation (years) | 50.1 (41.1; 62.0) |
| Body mass index (kg/m2) | 28.2 (24.3; 31.3) |
| Tumour type | Papillary 69%, follicular 19%, other 12% |
| Tumour stage at initial presentation | pT1 46%, pT2 20%, pT3 12%, pT4 3%, N1 12%, M1 4% |
| Ablative treatment | surgery 100%, plus radioiodine 92.5% |
| LT4 dose (µg/day) | 150 (125; 175) |
| Weight-adjusted LT4 dose (µg/kg BW/day) | 1.84 (1.62; 2.14) |
| FT3 (pmol/l) | 5.15 (4.60; 5.80) |
| FT4 (pmol/l) | 22.3 (19.6; 25.4) |
| TSH (mIU/l) | 0.07 (0.01; 0.46) |
| FT3–FT4 ratio | 0.23 (0.20; 0.26) |
| Deiodinase activity (nmol/s) | 21.6 (18.8; 24.2) |
1
Values shown are under nonhypothyroid (FT4 >10 pmol/l, TSH <4 mIU/l) stable conditions, excluding temporary LT4 withdrawal for radioiodine treatment.
BW, body weight; FT3, free triiodothyronine; FT4, free thyroxine; LT4, levothyroxine; TSH, thyroid stimulating hormone.